Encompass Health Corporation (EHC)

Environment story

Encompass Health discloses minimal environmental data. Scope 1, 2, and 3 emissions are undisclosed, with no stated net-zero target or renewable energy percentage. The company operates 173 inpatient rehabilitation hospitals with significant real estate and energy footprint but provides no public climate commitments, decarbonization initiatives, or sustainability reporting. No environmental controversies or resource-use violations are documented in the filing. The lack of disclosure triggers automatic penalties under the deterministic rules: -15 for undisclosed Scope 3, -15 for absent/post-2045 net-zero target, yielding a floor score of 70, then capped at 55 due to absence of supply-chain emissions disclosure relative to operational footprint (greenwashing detection).

Social story

Encompass Health demonstrates moderate social performance. The company reports 28,948 full-time equivalent employees and 355 contract labor FTEs as of 2025, with an employee-per-occupied-bed (EPOB) ratio of 3.37, indicating stable staffing relative to capacity. The 10-K emphasizes recruiting and retaining qualified personnel as a strategic priority and acknowledges labor cost pressures including sign-on bonuses and shift incentives, suggesting competitive compensation efforts. However, no CEO-to-worker pay ratio is disclosed, and diversity metrics (executive/board women and underrepresented racial/ethnic percentages) are absent from the filing. No union-suppression activities, strikes, or major labor disputes are documented in 2023–2025. Supply chain audits and human rights policies are not described. The company is subject to extensive employment law compliance requirements (wage/hour, occupational safety, HIPAA, anti-discrimination) with documented regulatory proceedings but no material violations cited in the filing. Score reflects absence of pay-ratio disclosure (-0, as threshold not exceeded with null data), lack of diversity data (-15 for unknown leadership diversity), no union issues (+0), and no documented supply-chain hazards (+0).

Governance story

Encompass Health exhibits solid governance practices with no major red flags. Board independence metrics are not explicitly disclosed in the filing, but no evidence of dual-class share structures or unequal voting rights is presented (standard single-class common stock structure assumed). The company has no documented active antitrust, consumer-safety, or financial-fraud regulatory proceedings; the 2019 settlement of DOJ investigation ($48 million, with express denial of wrongdoing and full release) is historical and resolved. Lobbying expenditures are not itemized in the filing, and no evidence of efforts to weaken climate or consumer-protection regulations is identified. The company faces extensive Medicare reimbursement audits and appeals (described in Risk Factors) but these are ordinary course regulatory compliance challenges, not governance failures. No shareholder litigation over climate proposals or anti-ESG activism is documented. Governance score reflects absence of clear board independence percentage (-0, as unknown), no dual-class penalty (+0), no active enforcement proceedings (+0), and no identified climate/consumer lobbying (-0).

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Encompass Health Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Encompass Health Corporation in the app for interactive charts and portfolio building.

More in Healthcare